Clinical trials have long recognized cancer treatment as a top priority. Different approaches have been devised for dealing with tumors of different types and at different stages. When it came to curing cancer, gene therapy was vital. The advancement of genome engineering technologies over the past thirty years has pushed forward gene therapy for the treatment and management of chronic diseases. It is the hope of researchers that one day they will be able to treat individuals with single gene disorders and complicated acquired diseases in a way that is both safe and successful. Gene delivery is a promising new method for detecting, diagnosing, and maybe treating cancer, made possible by recent developments in genetic engineering. Naked nucleic acid-based treatment, targeting microRNAs, oncolytic viral therapy, suicide gene-based therapy, targeting telomerase, cell-mediated gene therapeutics, and CRISPR/Cas9-based therapies are just few of the cancer medicines that have been created and tested in vitro and in vivo. This article provides a critical overview of the present and diverse cancer gene therapy methodologies, as well as a summary of the available viral and non-viral gene delivery mechanisms for gene therapy. In the future, biosafe carriers for gene products will play a crucial role in the prevention of cancer.
| Published in | American Journal of Clinical and Experimental Medicine (Volume 12, Issue 2) |
| DOI | 10.11648/j.ajcem.20241202.12 |
| Page(s) | 13-19 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Gene Therapy, Cancer Treatment, Gene Editing, Tissues
| [1] | Siegel, Rebecca L., Kimberly D. Miller, Stacey A. Fedewa, Dennis J. Ahnen, Reinier GS Meester, Afsaneh Barzi, and Ahmedin Jemal, Colorectal cancer statistics," CA: a cancer journal for clinicians. 2017, 67(3), 177-193. |
| [2] | Yang, Xiaoliang, Weidong Cao, Xiaofeng Wang, Xiang Zhang, Wei Zhang, Zenggang Li, and Haian Fu., Down-regulation of 14-3-3zeta reduces proliferation and increases apoptosis in human glioblastoma." Cancer Gene Therapy. 2020, 27(6), 399-411. |
| [3] | Shen, Zheyu, Jibin Song, Bryant C. Yung, Zijian Zhou, Aiguo Wu, and Xiaoyuan Chen. Emerging strategies of cancer therapy based on ferroptosis." Advanced Materials, 2018, 30(12), 1704007. |
| [4] | Torre, Lindsey A., Freddie Bray, Rebecca L. Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, and Ahmedin Jemal. "Global cancer statistics. CA: a cancer journal for clinicians, 2012, 65(2), 87-108. |
| [5] | Sun, Yu., Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures." Medicinal research reviews, 2015, 35(2) |
| [6] | Cho, Kwangjae, X. U. Wang, Shuming Nie, Zhuo Chen, and Dong M. Shin, “Therapeutic nanoparticles for drug delivery in cancer", Clinical cancer research, 2008, 14(5), 1310-1316. |
| [7] | Han, Kai, Si Chen, Wei-Hai Chen, Qi Lei, Yun Liu, Ren-Xi Zhuo, and Xian-Zheng Zhang, "Synergistic gene and drug tumor therapy using a chimeric peptide.", Biomaterials, 2013, 34 (19), 4680-4689. |
| [8] | Hu, Shoushan, Alifu Alimire, Yancheng Lai, Haonan Hu, Zhuo Chen, and Yi Li., “Trends and frontiers of research on cancer gene therapy from 2016 to 2020: a bibliometric analysis.”, Frontiers in Medicine, 2021, (8), 740710. |
| [9] | S. A Rosenberg, Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer, Journal of clinical Oncology, 1992, 10(2). |
| [10] | Wang L, Liu G, Zheng L, Long H, Liu Y. A new era of gene and cell therapy for cancer: a narrative review. Ann Transl Med 2023; 11(9): 321. |
| [11] | Anderson, W. French, ed., “The beginning.", Human gene therapy, 1990, 1(4), 371-372. |
| [12] | Friedmann, Theodore. “A brief history of gene therapy”, Nature genetics”, 1992, 2(2): 93-98 |
| [13] | Arber, Werner, and Stuart Linn. "DNA modification and restriction." Annual review of biochemistry, 1969, 38(1), 467-500. |
| [14] | Johannsen, Wilhelm., “An analysis of Wilhelm Johannsen’s term”, genotype, 1975, 1909-26 (79): 1-4. |
| [15] | Portin, Petter, and Adam Wilkins, “The evolving definition of the term, gene” Genetics, 2017, 205(4), 1353-1364. |
| [16] | Lehman, I. R. “DNA Ligase: Structure, Mechanism, and Function: The joining of DNA chains by DNA ligase is an essential component of DNA repair. replication, and recombination." Science, 1974, 186 (4166), 790-797. |
| [17] | Mulligan, Richard C. “The basic science of gene therapy", Science, 1993, 260 (5110), 926-932. |
| [18] | Williams, David A., Ihor R. Lemischka, David G. Nathan, and Richard C. Mulligan, “Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse." Nature, 1984, 310(5977), 476-480. |
| [19] | Junghans, Richard P. “The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective." Cancer Gene Therapy, 2017, 24(3), 89-99. |
| [20] | Xu, Qumiao, Hizkia Harto, Robert Berahovich, Shirley Xu, Hua Zhou, Vita Golubovskaya, and Lijun Wu., “Generation of CAR-T cells for cancer immunotherapy", Cancer Immunosurveillance: Methods and Protocols, 2019, 1884, 349-360. |
| [21] | Mansouri, Vahid, Nima Beheshtizadeh, Maliheh Gharibshahian, Leila Sabouri, Mohammad Varzandeh, and Nima Rezaei. Recent advances in regenerative medicine strategies for cancer treatment." Biomedicine & Pharmacotherapy, 2021, (141): 111875. |
| [22] | Jayaraman, Jayapriya, Michael P. Mellody, Andrew J. Hou, Ruchi P. Desai, Audrey W. Fung, An Huynh Thuy Pham, Yvonne Y. Chen, and Weian Zhao, “CAR-T design: Elements and their synergistic function." E BioMedicine, 2020, 58, 102931 |
| [23] | Tokarew, Nicholas, Justyna Ogonek, Stefan Endres, Michael von Bergwelt-Baildon, and Sebastian Kobold., “Teaching an old dog new tricks: next-generation CAR T cells.", British journal of cancer, 2019, 120 (1), 26-37. |
| [24] | Jackson, Hollie J., Sarwish Rafiq, and Renier J. Brentjens. "Driving CAR T-cells forward”, Nature reviews Clinical oncology, 2016, 13(6), 370-383. |
| [25] | Zhao, Qijie, Yu Jiang, Shixin Xiang, Parham Jabbarzadeh Kaboli, Jing Shen, Yueshui Zhao, Xu Wu., “Engineered TCR-T cell immunotherapy in anticancer precision medicine, pros and cons.", Frontiers in immunology, 2021, (12), 658753. |
| [26] | Fu, Chunmei, Li Zhou, Qing-Sheng Mi, and Aimin Jiang, “DC-based vaccines for cancer immunotherapy." Vaccines, 2020, 8(4), 706. |
| [27] | Bano I, Malhi M, Zhao M, Giurgiulescu L, Sajjad H, Kieliszek M. “A review on cullin neddylation and strategies to identify its inhibitors for cancer therapy” 3 Biotech. 2022; (12), 103. |
| [28] | Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021; 12: |
| [29] | Watson, James D., and Francis HC Crick, “Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid.” Nature, 1953, 171(4356), 737-738. |
| [30] | Wolff, Jon A., and Joshua Lederberg., “An early history of gene transfer and therapy." Human Gene Therapy”, 1994, 5(4): 469-480. |
| [31] | Cross, Deanna, and James K. Burmester,“Gene therapy for cancer treatment: past, present and future." Clinical medicine & research, 2006, 4(3), 218-227. |
| [32] | Rosenberg, Steven A., Paul Aebersold, Kenneth Cornetta, Attan Kasid, Richard A. Morgan, Robert Moen, Evelyn M. Karson, “Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.", New England Journal of Medicine, 1990, 323(9), 570-578. |
| [33] | Fritz, Jill M., and Michael J. Lenardo, “Development of immune checkpoint therapy for cancer.", Journal of Experimental Medicine, 2019, 216(6), 1244-1254. |
| [34] | Cavazzana, Marina, Emmanuelle Six, Chantal Lagresle-Peyrou, Isabelle André-Schmutz, and Salima Hacein-Bey-Abina, “Gene therapy for X-linked severe combined immunodeficiency: where do we stand?.", Human gene therapy, 2016, 27(2), 108-116. |
| [35] | Zheng, Meijun, Jianhan Huang, Aiping Tong, and Hui Yang. "Oncolytic viruses for cancer therapy: barriers and recent advances”: Molecular Therapy-Oncolytics, 2019, (15): 234-247. |
| [36] | Ferrucci, Pier Francesco, Laura Pala, Fabio Conforti, and Emilia Cocorocchio. "Talimogene laherparepvec (T-VEC), an intralesional cancer immunotherapy for advanced melanoma." Cancers, 2021, 13(6), 1383. |
| [37] | Dai, Hanren, Yao Wang, Xuechun Lu, and Weidong Han. "Chimeric antigen receptors modified T-cells for cancer therapy, Journal of the National Cancer Institute, 2016, 108 (7). |
| [38] | Sayed, Shady, Olga A. Sidorova, Alexander Hennig, Martina Augsburg, Catherine P. Cortés Vesga, Moustafa Abohawya, Lukas T. Schmitt, “Efficient correction of oncogenic KRAS and TP53 mutations through CRISPR base editing.", Cancer research, 2022, 82(17): 3002-3015. |
| [39] | Tian, Yaomei, Daoyuan Xie, and Li Yang, “Engineering strategies to enhance oncolytic viruses in cancer immunotherapy”, Signal Transduction and Targeted Therapy, 2022, 7(1): 117. |
| [40] | Nayerossadat, Nouri, Talebi Maedeh, and Palizban Abas Ali, "Viral and nonviral delivery systems for gene delivery." Advanced biomedical research, 2012, 1(1), 27 |
APA Style
Amin, M. H. (2024). An Overview of Emerging Trends in Gene Therapy for Cancer Treatment. American Journal of Clinical and Experimental Medicine, 12(2), 13-19. https://doi.org/10.11648/j.ajcem.20241202.12
ACS Style
Amin, M. H. An Overview of Emerging Trends in Gene Therapy for Cancer Treatment. Am. J. Clin. Exp. Med. 2024, 12(2), 13-19. doi: 10.11648/j.ajcem.20241202.12
AMA Style
Amin MH. An Overview of Emerging Trends in Gene Therapy for Cancer Treatment. Am J Clin Exp Med. 2024;12(2):13-19. doi: 10.11648/j.ajcem.20241202.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajcem.20241202.12,
author = {Muhammad Haider Amin},
title = {An Overview of Emerging Trends in Gene Therapy for Cancer Treatment
},
journal = {American Journal of Clinical and Experimental Medicine},
volume = {12},
number = {2},
pages = {13-19},
doi = {10.11648/j.ajcem.20241202.12},
url = {https://doi.org/10.11648/j.ajcem.20241202.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20241202.12},
abstract = {Clinical trials have long recognized cancer treatment as a top priority. Different approaches have been devised for dealing with tumors of different types and at different stages. When it came to curing cancer, gene therapy was vital. The advancement of genome engineering technologies over the past thirty years has pushed forward gene therapy for the treatment and management of chronic diseases. It is the hope of researchers that one day they will be able to treat individuals with single gene disorders and complicated acquired diseases in a way that is both safe and successful. Gene delivery is a promising new method for detecting, diagnosing, and maybe treating cancer, made possible by recent developments in genetic engineering. Naked nucleic acid-based treatment, targeting microRNAs, oncolytic viral therapy, suicide gene-based therapy, targeting telomerase, cell-mediated gene therapeutics, and CRISPR/Cas9-based therapies are just few of the cancer medicines that have been created and tested in vitro and in vivo. This article provides a critical overview of the present and diverse cancer gene therapy methodologies, as well as a summary of the available viral and non-viral gene delivery mechanisms for gene therapy. In the future, biosafe carriers for gene products will play a crucial role in the prevention of cancer.
},
year = {2024}
}
TY - JOUR T1 - An Overview of Emerging Trends in Gene Therapy for Cancer Treatment AU - Muhammad Haider Amin Y1 - 2024/05/24 PY - 2024 N1 - https://doi.org/10.11648/j.ajcem.20241202.12 DO - 10.11648/j.ajcem.20241202.12 T2 - American Journal of Clinical and Experimental Medicine JF - American Journal of Clinical and Experimental Medicine JO - American Journal of Clinical and Experimental Medicine SP - 13 EP - 19 PB - Science Publishing Group SN - 2330-8133 UR - https://doi.org/10.11648/j.ajcem.20241202.12 AB - Clinical trials have long recognized cancer treatment as a top priority. Different approaches have been devised for dealing with tumors of different types and at different stages. When it came to curing cancer, gene therapy was vital. The advancement of genome engineering technologies over the past thirty years has pushed forward gene therapy for the treatment and management of chronic diseases. It is the hope of researchers that one day they will be able to treat individuals with single gene disorders and complicated acquired diseases in a way that is both safe and successful. Gene delivery is a promising new method for detecting, diagnosing, and maybe treating cancer, made possible by recent developments in genetic engineering. Naked nucleic acid-based treatment, targeting microRNAs, oncolytic viral therapy, suicide gene-based therapy, targeting telomerase, cell-mediated gene therapeutics, and CRISPR/Cas9-based therapies are just few of the cancer medicines that have been created and tested in vitro and in vivo. This article provides a critical overview of the present and diverse cancer gene therapy methodologies, as well as a summary of the available viral and non-viral gene delivery mechanisms for gene therapy. In the future, biosafe carriers for gene products will play a crucial role in the prevention of cancer. VL - 12 IS - 2 ER -
Chariman Board of Governors, The University of Faisalabad, Faisalabad, Pakistan; Dental College, University of Medical, Faisalabad, Pakistan
